Table 1: Characteristics of participants in a cervical cancer screening event in the locomapa region, honduras.

Participants’ Characteristicsa

Overall

N = 449

Prior Pap

N = 316

No Prior Pap  

N = 133

HPV Positive

N = 71

HPV 16/18

N = 15

 

N (column %)

Sociodemographic

Age category (years)

<  21

20 (4.5)

6 (1.9)

14 (10.5)

4 (5.6)

0 (0.0)

     21-25

45 (10.0)

15 (4.8)

30 (22.6)

6 (8.5)

2 (13.3)

     26-30

58 (12.9)

29 (9.2)

29 (21.8)

12 (16.9)

3 (20.0)

     31-35

71 (15.8)

54 (17.1)

17 (12.8)

8 (11.3)

2 (13.3)

     36-40

54 (12.0)

36 (11.4)

18 (13.5)

10 (14.1)

2 (13.3)

     41-45

40 (8.9)

36 (11.4)

4 (3.0)

2 (2.8)

0 (0.0)

     46-50

41 (9.1)

34 (10.7)

7 (5.3)

10 (14.1)

3 (20.0)

> 50

120 (26.7)

106 (33.5)

14 (10.5)

19 (26.8)

3 (20.0)

Years of dducation 

     None

72 (16.6)

39 (12.8)

33 (25.4)

15 (22.7)

3 (23.1)

     1-3

76 (17.5)

54 (17.8)

22 (16.9)

12 (18.2)

2 (15.4)

     4-6

240 (55.3)

182 (59.9)

58 (44.6)

29 (43.9)

6 (46.2)

     7-9

22 (5.1)

16 (5.3)

6 (4.6)

4 (6.1)

0 (0.0)

> 9

24 (5.5)

13 (4.3)

11 (8.5)

6 (9.1)

2 (15.4)

% of Life residing in locomapa region 

     100

129 (31.7)

91 (31.5)

38 (32.2)

18 (27.3)

7 (63.6)

     50- < 100

110 (27.0)

90 (31.1)

20 (17.0)

18 (27.3)

3 (27.3)

< 50

168 (41.3)

108 (37.4)

60 (50.8)

30 (45.5)

1 (9.1)

Personal and Family History

Age at first menstrual period (yrs.) 

< 13

76 (17.0)

53 (16.8)

23 (17.3)

11 (15.7)

4 (23.7)

13-14

235 (52.5)

162 (51.4)

73 (54.9)

38 (54.3)

8 (53.3)

> 14

137 (30.6)

100 (31.8)

37 (27.8)

21 (30.0)

3 (20.0)

Number of children  

     None

7 (1.6)

3 (1.0)

4 (3.0)

3 (4.2)

1 (6.7)

     1-2

124 (27.6)

73 (23.1)

51 (38.4)

20 (28.2)

4 (26.7)

     3-4

132 (29.4)

105 (33.2)

27 (20.3)

20 (28.2)

2 (13.3)

     5-8

136 (30.3)

101 (32.0)

35 (26.3)

18 (25.4)

6 (40.0)

> 8

50 (11.1)

34 (10.8)

16 (12.0)

10 (14.1)

2 (13.3)

Age at birth of first child (yrs.)

<  18

172 (39.1)

105 (33.7)

67 (52.3)

29 (43.3)

9 (64.3)

     18-20

157 (35.7)

118 (37.8)

39 (30.5)

18 (26.9)

0 (0.0)

     21-25

87 (19.8)

69 (22.1)

18 (14.1)

14 (20.9)

3 (21.4)

>  25

24 (5.5)

20 (6.4)

4 (3.1)

6 (9.0)

2 (14.3)

Number of sexual partners (cumulative) 

     1

256 (57.0)

181 (57.3)

75 (56.4)

35 (49.3)

12 (80.0)

     2

180 (40.1)

123 (38.9)

57 (42.9)

31 (43.7)

2 (13.3)

     3-5

13 (2.9)

12 (3.8)

1 (1.0)

5 (7.0)

1 (6.7)

Regularly use family planning method 

     Oral contraceptives

119 (26.5)

93 (33.0)

26 (20.2)

19 (28.8)

7 (50.0)

     Condom

1 (< 1)

1 (< 1)

0 (0.0)

1 (1.5)

0 (0.0)

     Other

98 (21.8)

69 (24.5)

47 (36.4)

12 (18.2)

1 (7.1)

     None

193 (47.0)

 137 (48.6)

56 (43.4)

34 (51.5)

6 (42.9)

Family history of cervical cancer with first degree relative 

     None

417 (95.4)

289 (94.4)

128 (97.7)

67 (95.7)

14 (93.3)

     One or more

20 (4.6)

17 (5.6)

3 (2.3)

3 (4.3)

1 (6.7)

Knowledge and perceptions

Had heard about cervical cancer screening tests before Jornada

     Yes - Pap test

336 (74.8)

271 (85.8)

65 (48.9)

54 (76.1)

10 (66.7)

     Yes - doctor inspects cervix

39 (8.7)

29 (9.2)

10 (7.5)

5 (7.0)

10 (6.67)

     Yes - Pap test and doctor  inspects cervix

2 (< 1)

1 (< 1)

1 (1.5)

0 (0.0)

0 (0.0)

     No

72 (16.0)

15 (4.8)

57 (42.9)

12 (16.9)

4 (26.7)

Had heard about human papillomavirus before Jornada 

     Yes -  Heard that HPV can cause cervical cancer

183 (41.3)

138 (44.1)

45 (34.6)

34 (48.6)

6 (40.0)

     Yes -  Had NOT heard that HPV can cause cervical cancer

49 (11.1)

38 (12.1)

11 (8.5)

7 (10.0)

3 (20.0)

     No

211 (47.6)

137 (43.8)

74 (56.9)

29 (41.4)

6 (40.0)

If given opportunity, would want to get HPV vaccine 

     Yes

398 (90.1)

280 (89.7)

118 (90.8)

61 (87.1)

3 (20.0)

     No

44 (9.9)

32 (10.3)

12 (9.2)

9 (12.9)

12 (80.0)

If given opportunity, would you want daughter(s) to get HPV vaccine 

     Yes

398 (89.8)

280 (90.0)

118 (89.4)

63 (88.7)

3 (20.0)

     No

45 (10.2)

31 (10.0)

14 (10.6)

8 (11.3)

12 (80.0)

Access

 

 

 

 

 

How they heard about the Jornadab

     Community leader

291 (64.8)

201 (63.6)

90 (67.7)

43 (60.6)

10 (66.7)

     Radio

28 (6.2)

23 (7.3)

5 (3.8)

2 (2.8)

0 (0.0)

     Television

2 (< 1)

2 (< 1)

0 (0.0)

0 (0.0)

0 (0.0)

     Told by family/friends

131 (29.2)

97 (30.7)

34 (25.6)

27 (38.0)

5 (33.3)

     Other

19 (4.2)

14 (4.4)

5 (3.8)

0 (0.0)

0 (0.0)

Mode of transportation to screening event

     Bus provided for event

166 (37.1)

111 (35.2)

55 (41.4)

30 (42.3)

8 (53.3)

     Public bus

5 (1.1)

3 (1.0)

2 (1.5)

1 (1.4)

0 (0.0)

     Car/Truck

22 (4.9)

21 (6.7)

1 (1.0)

7 (9.9)

2 (13.3)

     Walked

246 (54.9)

172 (54.6)

74 (55.6)

32 (45.1)

5 (33.3)

     Horse/Cart

4 (1.0)

4 (1.3)

0 (0.0)

0 (0.0)

0 (0.0)

     Other

5 (1.1)

4 (1.3)

1 (1.0)

1 (1.4)

0 (0.0)

Mode of transportation most likely to use when seeking healthcare

     Bus

160 (35.9)

106 (33.8)

54 (40.9)

28 (39.4)

6 (40.0)

     Car/Truck

5 (1.1)

5 (1.6)

0 (0.0)

2 (2.8)

1 (6.7)

     Walking

277 (62.1)

199 (63.4)

78 (59.1)

41 (57.8)

8 (53.3)

     Horse/Cart

1 (< 1)

1 (< 1)

0 (0.0)

0 (0.0)

0 (0.0)

     Other

3 (1.0)

3 (1.0)

0 (0.0)

0 (0.0)

0 (0.0)

Time to nearest Pap test location

≤ 30 min.

156 (34.8)

125 (39.6)

31 (23.5)

25 (35.2)

5 (33.3)

> 30 min. - 1 hour

75 (16.7)

50 (15.8)

25 (18.9)

11 (15.5)

2 (13.3)

> 1-2 hours

131 (29.2)

91 (28.8)

40 (30.3)

24 (33.8)

5 (33.3)

> 2 hours

86 (19.2)

50 (15.8)

36 (27.3)

11 (15.5)

3 (20.0)

 

aMissing (N): Education (15), % of Life residing in Locomapa region (42), Age at first menstrual period (1), Number of children (7),  Age at first birth (9), Regular use of family planning method (38), Family history of cervical cancer (12), Heard of cervical cancer screening test with prior Pap test (67), Heard of HPV before Jornada (6), If given opportunity, would want to get HPV vaccine (7), If given opportunity, would you want daughter(s) to get HPV vaccine (6), Mode of transportation to screening event(1), Mode of transportation most likely to use when seeking healthcare (3), Time to nearest Pap test location (1).

bNot mutually exclusive